نتایج جستجو برای: alisertib

تعداد نتایج: 124  

2015
Feng Wang Hai Li Xiao-Gang Yan Zhi-Wei Zhou Zhi-Gang Yi Zhi-Xu He Shu-Ting Pan Yin-Xue Yang Zuo-Zheng Wang Xueji Zhang Tianxing Yang Jia-Xuan Qiu Shu-Feng Zhou

Pancreatic cancer is the most aggressive cancer worldwide with poor response to current therapeutics. Alisertib (ALS), a potent and selective Aurora kinase A inhibitor, exhibits potent anticancer effects in preclinical and clinical studies; however, the effect and underlying mechanism of ALS in the pancreatic cancer treatment remain elusive. This study aimed to examine the effects of ALS on cel...

2017
Madhu Kollareddy Alice Sherrard Ji Hyun Park Marianna Szemes Kelli Gallacher Zsombor Melegh Sebastian Oltean Martin Michaelis Jindrich Cinatl Abderrahmane Kaidi Karim Malik

Neuroblastoma is a biologically and clinically heterogeneous pediatric malignancy that includes a high-risk subset for which new therapeutic agents are urgently required. As well as MYCN amplification, activating point mutations of ALK and NRAS are associated with high-risk and relapsing neuroblastoma. As both ALK and RAS signal through the MEK/ERK pathway, we sought to evaluate two previously ...

2015
Yong-Hui Ding Zhi-Wei Zhou Chun-Fang Ha Xue-Yu Zhang Shu-Ting Pan Zhi-Xu He Jeffrey L Edelman Dong Wang Yin-Xue Yang Xueji Zhang Wei Duan Tianxin Yang Jia-Xuan Qiu Shu-Feng Zhou

Ovarian cancer is a leading killer of women, and no cure for advanced ovarian cancer is available. Alisertib (ALS), a selective Aurora kinase A (AURKA) inhibitor, has shown potent anticancer effects, and is under clinical investigation for the treatment of advanced solid tumor and hematologic malignancies. However, the role of ALS in the treatment of ovarian cancer remains unclear. This study i...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
E Claire Dees Roger B Cohen Margaret von Mehren Thomas E Stinchcombe Hua Liu Karthik Venkatakrishnan Mark Manfredi Howard Fingert Howard A Burris Jeffrey R Infante

PURPOSE This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational oral drug MLN8237 (alisertib), a small-molecule Aurora A kinase (AAK) inhibitor, in 87 adult patients with advanced solid tumors. EXPERIMENTAL DESIGN Sequential cohorts of patients received MLN8237 5 to 150 mg orally once daily or twice daily for 7, 14, or 21 days, followed...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Vikas Sehdev Ahmed Katsha Janet Arras Dunfa Peng Mohammed Soutto Jeffrey Ecsedy Alexander Zaika Abbes Belkhiri Wael El-Rifai

PURPOSE Suppression of P53 (tumor protein 53) transcriptional function mediates poor therapeutic response in patients with cancer. Aurora kinase A (AURKA) and human double minute 2 (HDM2) are negative regulators of P53. Herein, we examined the role of AURKA in regulating HDM2 and its subsequent effects on P53 apoptotic function in gastric cancer. EXPERIMENTAL DESIGN Primary tumors and in vitr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید